Abstracts tagged "IL-6"

Abstract Number: 1208 • ACR Convergence 2021
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Andrés Ponce¹, Beatriz Frade-Sosa², Ramirez Julio³, Núria Sapena¹, Roberto Gumucio², Virginia Ruiz-Esquide², Rosa Morlà², Marta Bassas², Juan D Cañete⁴ and Jose A Gomez-Puerta², ¹Rheumatology Department, Hospital Clínic, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
Abstract Number: 1 • 2019 ACR/ARP Annual Meeting
Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Mahamudul Haque ¹, Bhanupriya Madarampalli ² and Salahuddin Ahmed ³, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, Spokane, WA, ²University of Washington, Seattle, WA, ³Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and joint destruction caused by pro-inflammatory cytokines. Progressive joint damage is also an…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…
Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Vivian Bykerk¹, Wenhui Wei ², Susan Boklage ², Toshio Kimura ², Stefano Fiore ³ and Gregory St John ⁴, ¹Hospital for Special Surgery, New York City, NY, ²Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…
Abstract Number: 1707 • 2019 ACR/ARP Annual Meeting
IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Zongfei Ji¹, Rongyi Chen ², Xiaomeng Cui ², Lili Ma ², Xiufang Kong ³, Lingying Ma ², Ying Sun ², Xiaomin Dai ², Zhuojun Zhang ², Huiyong Chen ² and Lindi Jiang ², ¹Department of Rheumatology, Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ²Zhongshan hospital, Fudan University, Shanghai, China (People's Republic), ³University of Michigan & Fudan University, Ann Arbor, MI
Background/Purpose: Considering the unsatisfied effect of conventional therapy, to investigate the pathogenesis of IgG4-related disease (IgG4-RD) is crucial to explore novel treatment strategies. This study…
Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Mahamudul Haque¹, Madeline McDougal ¹, Anil Singh ¹ and Salahuddin Ahmed ², ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Jeffrey Curtis¹, Yong Lin ², Karthinathan Thangavelu ³, Marina Stanislav ⁴, Gregory St John ⁵, Antonio Gómez-Centeno ⁶, Carlo Selmi ⁷, Thomas Huizinga ⁸, José Antonio Maldonado-Cocco ⁹, Marwan Bukhari ¹⁰ and Frank Buttgereit ¹¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Bridgewater, NJ, ³Sanofi Genzyme, Boston, MA, ⁴V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Corporació Sanitària Parc Taulí, Barcelona, Spain, ⁷Humanitas Research Hospital, University of Milan, Milan, Italy, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Buenos Aires University School of Medicine, Buenos Aires, Argentina, ¹⁰Lancaster University Medical School, Lancaster, United Kingdom, ¹¹Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 2493 • 2019 ACR/ARP Annual Meeting
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Maria Elisa Acosta¹, Luis Gomez-Lechon ¹, Guadalupe Manzano Canabal ¹, Olga Compan ², Cristina Hidalgo ³, Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clinico Universitario de Salamanca, SALAMANCA, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: The activation of the Th-1 and Th-17 lymphocytes response seems to be one of the causes associated with PsA onset. During this process cytokines…
Abstract Number: 2494 • 2019 ACR/ARP Annual Meeting
Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Luis Gomez-Lechon¹, Maria Elisa Acosta ¹, Guadalupe Manzano Canabal ¹, Olga Compan ¹, Cristina Hidalgo ², Olga Martinez ¹, Ana Turrión ¹, Javier del Pino ¹ and Carlos Montilla ¹, ¹Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ²Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease that is included in the group of spondyloarthritis. Although PsA has its own clinical characteristics, it has…
Abstract Number: L08 • 2018 ACR/ARHP Annual Meeting
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Anita Boyapati¹, Jérôme Msihid², Sergio Schwartzman³, Ernest Choy⁴, Mark C. Genovese⁵, Gerd R. Burmester⁶, Gordon Lam⁷, Toshio Kimura¹, Jonathan Sadeh⁸ and Neil M.H. Graham¹, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi Chilly-Mazarin, Chilly-Mazarin, NJ, France, ³Hospital for Special Surgery, New York, NY, ⁴CREATE Center, Cardiff University School of Medicine, Cardiff, Great Britain, ⁵Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ⁶Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁷Atrium Health, Charlotte, NC, ⁸Sanofi, Bridgewater, NJ
Background/Purpose: Clinical application of biomarkers to predict response to therapy is the next frontier in RA. Despite the key role of IL-6 in RA, the…
Abstract Number: 720 • 2018 ACR/ARHP Annual Meeting
Interkeukin-6 Level in Cerebrospinal Fluid As a Biomarker for Systemic Lupus Erythematosus Patients with Longitudinally Extensive Transverse Myelitis like Neuromyelitis Optica Spectrum Disease
Yasuhiro Hasegawa¹, Yoshiyuki Arinuma¹, Kazuma Ino¹, Takumi Muramatsu¹, Junichi Kondo¹, Yu Matsueda¹, Takayuki Hoshiyama¹, Toshihiro Tono¹, Tatsuhiko Wada¹, Tatsuo Nagai² and Sumiaki Tanaka¹, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan
Background/Purpose: Demyelinating syndrome in NPSLE includes the wide range of lesions similar to multiple sclerosis (MS). Recently, the diagnostic criteria for neuromyelitis optica spectrum disease…
Abstract Number: 2529 • 2018 ACR/ARHP Annual Meeting
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
John Tesser¹, Gregory St. John², Toshio Kimura², Stefano Fiore³, Maureen Rischmueller⁴, José A. Maldonado-Cocco⁵, Jürgen Braun⁶ and Jeffrey Kaine⁷, ¹Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Clinical Science, Sanofi Genzyme, Bridgewater, NJ, ⁴The University of Adelaide, Adelaide, Australia, ⁵Buenos Aires University School of Medicine, Buenos Aires, Argentina, ⁶Ruhr-University Bochum, Bochum, Germany, ⁷Sarasota Arthritis Research Center, Sarasota, FL
Background/Purpose: Sarilumab showed efficacy in RA and superiority to placebo and adalimumab in Phase 3 trials. This post hoc analysis investigated LFT levels in three…
Abstract Number: 905 • 2018 ACR/ARHP Annual Meeting
Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroeder⁵, Brian Kabat⁵, Carol Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, Philip Seo⁹, Robert F. Spiera¹⁰, Eugene William St. Clair¹¹, Fernando Fervenza¹², John H. Stone¹³, Paul A. Monach¹⁴, Ulrich Specks¹⁵ and Peter A. Merkel¹⁶, ¹Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Rheumatology, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medicine, Duke University Medical Center, Durham, NC, ¹²Nephrology, Mayo Clinic, Rochester, MN, ¹³Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁵Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The deregulated overproduction of interleukin (IL)-6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases. We aimed to investigate serum IL-6 levels (sIL-6)…
Abstract Number: 2776 • 2018 ACR/ARHP Annual Meeting
Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
Nicolò Pipitone¹, Francesco Muratore², Ione Tamagnini³, Alberto Cavazza⁴, Luca Cimino⁵, Luigi Boiardi², Giovanna Restuccia⁶, Martina Bonacini⁷, Stefania Croci⁷ and Carlo Salvarani⁸, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, ⁷Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To evaluate if interleukin-6 (IL-6) expression in the temporal artery biopsy (TAB) specimens may differentiate patients with giant cell arteritis (GCA) from those without.…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.